Business Context and Reporting Period
This Form 8-K is a current report filed by Aerovate Therapeutics, Inc. (not Jade Biosciences, Inc.) on October 6, 2024. The registrant is a Delaware corporation with its principal executive offices in Waltham, Massachusetts, and its common stock trades on The Nasdaq Global Market under the symbol AVTE. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the departure of a director:
- Resignation: Maha Katabi, Ph.D., resigned from the Board of Directors, effective October 6, 2024.
- Committee Roles: Dr. Katabi also resigned from the Audit Committee and the Compensation Committee.
- Reason: The resignation was voluntary and not the result of any disagreement with the Company regarding operations, practices, or policies.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks, contingencies, or unusual items were disclosed in this report beyond the standard disclosure regarding the director's departure.
Investor Verification Checklist
- Verify the updated composition of the Board of Directors and committee memberships following Dr. Katabi's departure.
- Confirm whether the resignation impacts the quorum or independence requirements for the Audit or Compensation Committees.
- Review subsequent filings for any new director appointments to fill the vacancy.